3 buys whatever the EU referendum result: AstraZeneca plc, YouGov plc and Cobham plc

These three stocks look set to perform well whether Leave or Remain win today’s vote: AstraZeneca plc (LON: AZN), YouGov plc (LON: YOU) and Cobham plc (LON: COB).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

So, the EU referendum is finally upon us and many investors may be wondering which stocks are set to perform well given a Remain or Leave victory. Certainly, there are many examples of potential winners given either result, but there are also stocks that could be set to record stunning share price gains whether the UK stays in or quits the EU.

One such is AstraZeneca (LSE: AZN). Its status as an international pharmaceutical company means that it’s more dependent on the ups and downs of the patent cycle rather than the booms and busts of the UK economy. And on the patent front it appears to be making strong progress with its acquisition strategy improving AstraZeneca’s treatment pipeline so that it’s on track to return to positive earnings growth over the medium term.

Furthermore, AstraZeneca is unlikely to slow down its pace of acquisitions, with the company having excellent cash flow, which affords it tremendous financial firepower. For example, in the last three years AstraZeneca’s free cash flow has averaged $4.9bn per annum and so it seems able to afford to spend further in order to beef up its pipeline. And with that cash flow supporting a yield of 5%, the company’s income potential remains upbeat – especially while interest rates are at rock bottom.

Headline grabber

Also offering upbeat future prospects whatever the EU referendum result is YouGov (LSE: YOU). Clearly, it has been in the headlines a lot more than usual recently, with its polling segment offering up predictions of whether Leave or Remain will win the vote. This could provide a boost to YouGov’s earnings in the short run and with the company expected to increase its net profit by 11% this year and by a further 13% next year, it seems to be performing well.

In fact, YouGov has an excellent track record of earnings growth, with its bottom line rising in each of the last five financial years. And with its shares trading on a price-to-earnings growth (PEG) ratio of just 1.6, they seem to offer a wide margin of safety for long-term investors. Therefore, whether the UK leaves or stays in the EU, YouGov seems to be a sound buy.

Contract wins

Meanwhile, aerospace company Cobham (LSE: COB) has today announced that it has been awarded a contract by Airbus to provide satellite communications to single-aisle and long-range aircraft families. The contract could be worth as much as $200m and will see aircraft being fitted with the communications technology from 2018 onwards. It’s the second major contract Cobham has won with Airbus in the last two months.

Clearly, Cobham has experienced a challenging period of late and its bottom line is due to fall by 22% this year. However, with it being geographically highly diversified and more reliant on the global economy than the UK economy, its return to growth next year seems to be less dependent on the outcome of today’s referendum than is the case for a number of its index peers. And with it trading on a price-to-earnings (P/E) ratio of 11.9, it seems to offer a sufficiently wide margin of safety to merit investment at the present time.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares of AstraZeneca. The Motley Fool UK has recommended AstraZeneca. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young Black man sat in front of laptop while wearing headphones
Investing Articles

Down 53% in a year! I reckon this oversold FTSE 100 stock is now ripe for a comeback

This FTSE 100 stock has fallen out of fashion with investors, but Harvey Jones reckons the sell-off has gone too…

Read more »

Young Asian man drinking coffee at home and looking at his phone
Investing Articles

How much second income would I get if I put £10k into dirt cheap Centrica shares?

Centric shares have been looking incredibly cheap despite rocketing in recent years. Harvey Jones wonders whether this is an opportunity…

Read more »

artificial intelligence investing algorithms
Investing Articles

If I’d invested £10k in AstraZeneca shares three months ago here’s what I’d have now

Harvey Jones is kicking himself for failing to buy AstraZeneca shares before the took off. Is there still a decent…

Read more »

A senior group of friends enjoying rowing on the River Derwent
Investing Articles

How I’d find shares to buy for an early retirement

Christopher Ruane explains some of the factors he considers when looking for shares to buy that could potentially help him…

Read more »

Investing Articles

Why I’d snap up bargain UK shares to try and build wealth

Christopher Ruane explains how he hopes to find high-quality UK shares selling at attractive prices, to help him build wealth…

Read more »

Young Caucasian woman at the street withdrawing money at the ATM
Investing Articles

Here’s how I’d target a £2k annual second income from a £20k Stocks & Shares ISA

Our writer explains how he’d try to earn thousands of pounds annually in dividends by investing a £20k ISA in…

Read more »

Mother and Daughter Blowing Bubbles
Investing Articles

5 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Investing Articles

The £20k Stocks and Shares ISA might be one of the better things about living in the UK

The £20k Stocks and Shares ISA doesn't have many equivalents in other countries. Here's why these accounts can help UK…

Read more »